Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Evotec price target raised to EUR 32 from EUR 30 at RBC Capital » 12:10
11/20/20
11/20
12:10
11/20/20
12:10
EVTCY

Evotec

$0.00 /

+ (+0.00%)

RBC Capital analyst Zoe…

RBC Capital analyst Zoe Karamanoli raised the firm's price target on Evotec to EUR 32 from EUR 30 and keeps an Outperform rating on the shares.

ShowHide Related Items >><<
EVTCY Evotec
$0.00 /

+ (+0.00%)

EVTCY Evotec
$0.00 /

+ (+0.00%)

09/10/20 RBC Capital
Evotec initiated with an Outperform at RBC Capital
09/01/20 Citi
Evotec initiated with a Buy at Citi
05/12/20 Deutsche Bank
Deutsche Bank affirms Buy on Evotec ahead of Q1 results
03/12/20 Deutsche Bank
Evotec price target raised to EUR 28 from EUR 25 at Deutsche Bank
Over a month ago
Hot Stocks
Evotec receives $6M payment from Bristol-Myers following portfolio expansion » 06:25
10/08/20
10/08
06:25
10/08/20
06:25
EVTCY

Evotec

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$60.42 /

+2.7 (+4.68%)

Evotec (EVTCY) announced…

Evotec (EVTCY) announced that the company has received a $6M payment from Bristol-Myers (BMY) following the decision to expand the portfolio by another drug discovery project. Evotec and Bristol-Myers initiated the collaboration in 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases. Currently approved drugs only offer short-term management of patients' symptoms and there is a huge unmet medical need for therapies that slow down or reverse disease progression in the field of neurodegenerative diseases. This collaboration pursues an approach to the discovery and development of novel medicines by leveraging several of Evotec's technology platforms in conjunction with the human iPSC-based platform. The partnership between Bristol-Myers and Evotec has already found several access points into neurodegenerative diseases. Adding yet another approach with direct relevance to Alzheimer's disease further complements the portfolio, which currently covers a range of incurable neurodegenerative conditions.

ShowHide Related Items >><<
BMY Bristol-Myers
$60.42 /

+2.7 (+4.68%)

EVTCY Evotec
$0.00 /

+ (+0.00%)

09/10/20 RBC Capital
Evotec initiated with an Outperform at RBC Capital
09/01/20 Citi
Evotec initiated with a Buy at Citi
05/12/20 Deutsche Bank
Deutsche Bank affirms Buy on Evotec ahead of Q1 results
03/12/20 Deutsche Bank
Evotec price target raised to EUR 28 from EUR 25 at Deutsche Bank
BMY Bristol-Myers
$60.42 /

+2.7 (+4.68%)

10/06/20 Wedbush
MyoKardia downgraded to Neutral from Outperform at Wedbush
10/06/20 Citi
MyoKardia downgraded to Neutral from Buy at Citi
10/06/20 BMO Capital
MyoKardia downgraded to Market Perform from Outperform at BMO Capital
10/05/20 Cowen
Bristol-Myers paid 'steep price' for MyoKardia, says Cowen
BMY Bristol-Myers
$60.42 /

+2.7 (+4.68%)

BMY Bristol-Myers
$60.42 /

+2.7 (+4.68%)

BMY Bristol-Myers
$60.42 /

+2.7 (+4.68%)

BMY Bristol-Myers
$60.42 /

+2.7 (+4.68%)

Initiation
Evotec initiated with an Outperform at RBC Capital » 06:14
09/10/20
09/10
06:14
09/10/20
06:14
EVTCY

Evotec

$0.00 /

+ (+0.00%)

RBC Capital analyst Zoe…

RBC Capital analyst Zoe Karamanoli initiated coverage of Evotec with an Outperform rating and EUR 30 price target. The analyst cites the company's opportunity as a "geared play on the early drug discovery and development market", adding that she is positive on Evotec's "diversified-risk" business model. Karamanoli further notes Evotec's efforts to differentiate itself relative to its peers by leveraging its "breadth of services" and development speed.

ShowHide Related Items >><<
EVTCY Evotec
$0.00 /

+ (+0.00%)

09/01/20 Citi
Evotec initiated with a Buy at Citi
05/12/20 Deutsche Bank
Deutsche Bank affirms Buy on Evotec ahead of Q1 results
03/12/20 Deutsche Bank
Evotec price target raised to EUR 28 from EUR 25 at Deutsche Bank
Initiation
Evotec initiated with a Buy at Citi » 06:35
09/01/20
09/01
06:35
09/01/20
06:35
EVTCY

Evotec

$0.00 /

+ (+0.00%)

Citi analyst Nick Nieland…

Citi analyst Nick Nieland initiated coverage of Evotec with a Buy rating and EUR 29.50 price target. The analyst likes Evotec's business model, calling if a profitable, end-to-end, fee-for-service offering to pharma, biotech and academia with "state-of-the-art" platforms and technologies, that "funds an underappreciated, extensive, albeit early stage biotech pipeline."

ShowHide Related Items >><<
EVTCY Evotec
$0.00 /

+ (+0.00%)

05/12/20 Deutsche Bank
Deutsche Bank affirms Buy on Evotec ahead of Q1 results
03/12/20 Deutsche Bank
Evotec price target raised to EUR 28 from EUR 25 at Deutsche Bank
Over a quarter ago
Recommendations
Deutsche Bank affirms Buy on Evotec ahead of Q1 results » 11:59
05/12/20
05/12
11:59
05/12/20
11:59
EVTCY

Evotec

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Deutsche Bank analyst Falko Friedrichs reiterated a Buy rating and EUR28 price target on Evotec ahead of the company's Q1 results.

ShowHide Related Items >><<
EVTCY Evotec
$0.00 /

+ (+0.00%)

03/12/20 Deutsche Bank
Evotec price target raised to EUR 28 from EUR 25 at Deutsche Bank
08/21/19 Deutsche Bank
Evotec upgraded to Buy from Hold at Deutsche Bank
Recommendations
Evotec price target raised to EUR 28 from EUR 25 at Deutsche Bank » 11:48
03/12/20
03/12
11:48
03/12/20
11:48
EVTCY

Evotec

$0.00 /

+ (+0.00%)

Deutsche Bank analyst…

Deutsche Bank analyst Falko Friedrichs raised the firm's price target on Evotec to EUR 28 from EUR 25 and keeps a Buy rating on the shares.

ShowHide Related Items >><<
EVTCY Evotec
$0.00 /

+ (+0.00%)

08/21/19 Deutsche Bank
Evotec upgraded to Buy from Hold at Deutsche Bank
04/10/19 Deutsche Bank
Evotec downgraded to Hold from Buy at Deutsche Bank

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.